RT Journal Article
SR Electronic
T1 Universal digital high resolution melt analysis for the diagnosis of bacteremia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.07.23295215
DO 10.1101/2023.09.07.23295215
A1 Aralar, April
A1 Goshia, Tyler
A1 Ramchandar, Nanda
A1 Lawrence, Shelley M.
A1 Karmakar, Aparajita
A1 Sharma, Ankit
A1 Sinha, Mridu
A1 Pride, David T.
A1 Kuo, Peiting
A1 Lecrone, Khrissa
A1 Chiu, Megan
A1 Mestan, Karen
A1 Sajti, Eniko
A1 Vanderpool, Michelle
A1 Lazar, Sarah
A1 Crabtree, Melanie
A1 Tesfai, Yordanos
A1 Fraley, Stephanie I.
YR 2023
UL http://medrxiv.org/content/early/2023/09/08/2023.09.07.23295215.abstract
AB Fast and accurate diagnosis of bloodstream infection is necessary to inform treatment decisions for septic patients, who face hourly increases in mortality risk. Blood culture remains the gold standard test but typically requires ∼15 hours to detect the presence of a pathogen. Here, we assess the potential for universal digital high-resolution melt (U-dHRM) analysis to accomplish faster broad-based bacterial detection, load quantification, and species-level identification directly from whole blood. Analytical validation studies demonstrated strong agreement between U-dHRM load measurement and quantitative blood culture, indicating that U-dHRM detection is highly specific to intact organisms. In a pilot clinical study of 21 whole blood samples from pediatric patients undergoing simultaneous blood culture testing, U-dHRM achieved 100% concordance when compared with blood culture and 90.5% concordance when compared with clinical adjudication. Moreover, U-dHRM identified the causative pathogen to the species level in all cases where the organism was represented in the melt curve database. These results were achieved with a 1 mL sample input and sample-to-answer time of 6 hrs. Overall, this pilot study suggests that U-dHRM may be a promising method to address the challenges of quickly and accurately diagnosing a bloodstream infection.Universal digital high resolution melt analysis for the diagnosis of bacteremia April Aralar, Tyler Goshia, Nanda Ramchandar, Shelley M. Lawrence, Aparajita Karmakar, Ankit Sharma, Mridu Sinha, David Pride, Peiting Kuo, Khrissa Lecrone, Megan Chiu, Karen Mestan, Eniko Sajti, Michelle Vanderpool, Sarah Lazar, Melanie Crabtree, Yordanos Tesfai, Stephanie I. FraleyCompeting Interest StatementS.I.F. is a scientific cofounder, director, and advisor of MelioLabs, Inc., and has an equity interest in the company. S.M.L. is an advisor of Melio and has equity interest. M.S. is co-founder and CEO of Melio and has equity interest. A.K. and A.S. are employees of Melio. NIAID award number R01AI134982 has been identified for conflict of interest management based on the overall scope of the project and its potential benefit to MelioLabs, Inc.; however, the research findings included in this particular publication may not necessarily relate to the interests of MelioLabs, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies.Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award number R01AI134982), a Burroughs Wellcome Fund Career Award at the Scientific Interface (award number 1012027 to S.I.F.), and UCSD CTRI, FISP, and AIM pilot grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical study protocol was reviewed and approved by the Institutional Review Board (IRB) and Ethics Committee (No. 191392) of the University of California, San Diego (UCSD) and Rady Childrens Hospital (RCHSD). Consent was not required for the scavenging of remnant CBC samples.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study, in accordance with IRB designated restrictions, are available from the corresponding author upon request.